Raymond E. Cabillot Sells 3,624 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,624 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $46.66, for a total value of $169,095.84. Following the completion of the transaction, the director now directly owns 356,022 shares in the company, valued at approximately $16,611,986.52. This represents a 1.01 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Stock Up 0.7 %

NASDAQ:PDEX opened at $45.30 on Thursday. The firm has a market cap of $147.63 million, a P/E ratio of 29.42 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. Pro-Dex, Inc. has a fifty-two week low of $16.18 and a fifty-two week high of $59.60. The firm has a 50-day simple moving average of $48.12 and a two-hundred day simple moving average of $32.49.

Institutional Trading of Pro-Dex

A number of institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in Pro-Dex by 2.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares in the last quarter. Renaissance Technologies LLC increased its stake in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after purchasing an additional 900 shares in the last quarter. FMR LLC increased its stake in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares in the last quarter. Bard Associates Inc. grew its stake in shares of Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after acquiring an additional 2,031 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares during the period. 15.28% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PDEX has been the subject of several analyst reports. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th. Ascendiant Capital Markets increased their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.